These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
214 related articles for article (PubMed ID: 25180155)
1. Significant clinical response to JAK1/2 inhibition in a patient with CSF3R-T618I-positive atypical chronic myeloid leukemia. Dao KH; Solti MB; Maxson JE; Winton EF; Press RD; Druker BJ; Tyner JW Leuk Res Rep; 2014; 3(2):67-9. PubMed ID: 25180155 [TBL] [Abstract][Full Text] [Related]
2. Efficacy of Ruxolitinib in Patients With Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia. Dao KT; Gotlib J; Deininger MMN; Oh ST; Cortes JE; Collins RH; Winton EF; Parker DR; Lee H; Reister A; Schultz ; Savage S; Stevens ; Brockett C; Subbiah N; Press RD; Raess PW; Cascio M; Dunlap J; Chen Y; Degnin C; Maxson JE; Tognon CE; Macey T; Druker BJ; Tyner JW J Clin Oncol; 2020 Apr; 38(10):1006-1018. PubMed ID: 31880950 [TBL] [Abstract][Full Text] [Related]
3. Analysis of CSF3R mutations in atypical chronic myeloid leukemia and other myeloid malignancies. Kim SY; Song IC; Kim J; Kwon GC Ann Diagn Pathol; 2024 Aug; 71():152317. PubMed ID: 38642470 [TBL] [Abstract][Full Text] [Related]
4. The Colony-Stimulating Factor 3 Receptor T640N Mutation Is Oncogenic, Sensitive to JAK Inhibition, and Mimics T618I. Maxson JE; Luty SB; MacManiman JD; Paik JC; Gotlib J; Greenberg P; Bahamadi S; Savage SL; Abel ML; Eide CA; Loriaux MM; Stevens EA; Tyner JW Clin Cancer Res; 2016 Feb; 22(3):757-64. PubMed ID: 26475333 [TBL] [Abstract][Full Text] [Related]